Company Overview and News

 
[Opinion] Oil Price, Sound Energy, Podcasts, and Finally…

2018-10-16 oilvoice
WTI $71.78 +44c, Brent $80.78 +35c, Diff -$9.00 -9c, NG $3.24 +8c Oil Price The oil price did end up on the day yesterday but at one stage looked like it was going to be nearer two bucks rather than the change that it turned out to be. With ‘KhashoggiGate' in full swing the worries about a full scale diplomatic feud between Washington and Riyadh heightened but towards the end of the day some pragmatism came into being as if the two big dogs realised that a fight was unwise.
HUR GEGYF GEGYY ZEE HRCXF SOU GENL SNEGF CANIF

 
[Press] Genel Energy PLC: Trading and Operations Update

2018-10-11 oilvoice
Genel Energy plc ('Genel' or 'the Company') issues the following trading and operations update in respect of Q3 2018. The information contained herein has not been audited and may be subject to further review.
GEGYF GEGYY GENL

 
[Press] Sterling Energy IMS

2018-10-11 oilvoice
Sterling Energy plc (the ‘Company' or 'Sterling') together with its subsidiary undertakings (the ‘Group') is today issuing its Interim Management Statement and financial results for the third quarter ended 30 September 2018. All figures are unaudited unless stated otherwise.
SEY GEGYF GEGYY GENL

 
[Press] Genel Energy PLC: Update on Tawke PSC

2018-10-10 oilvoice
Genel Energy plc ('Genel') notes that DNO ASA, as operator of the Tawke PSC (Genel 25% working interest), has today issued an update on licence activity.
GEGYF GEGYY DTNOY GENL DTNOF

 
[Press] Posting of Shareholder Materials and Proposed Director Appointments

2018-08-23 oilvoice
Wentworth, the Oslo Børs (OSE: WRL) and AIM (AIM: WRL) listed independent, East Africa-focused oil & gas company, announces that it has today published a Notice of Special Meeting of Shareholders, a Management Information Circular and Proxy Forms (the "Shareholder Materials") on its website (www.wentworthresources.com) and on NewsWeb (www.newsweb.oslobors.no/).
GEGYF PRTDF MATD CRNZF RKH GENL RCKHF GEGYY CNE MS FPM CRNCY

 
[Press] DNO Reports Payment for Tawke Deliveries

2018-08-20 oilvoice
Oslo, 20 August 2018 - DNO ASA, the Norwegian oil and gas operator, today reported receipt of USD 69.03 million as payment for May 2018 crude oil deliveries to the export market from the Tawke license in the Kurdistan region of Iraq. The funds will be shared by DNO and partner Genel Energy plc pro-rata to the companies' interests in the license.
GEGYF GEGYY DTNOY GENL DTNOF

 
DNO Reports Payment for Tawke Deliveries

2018-08-20 globenewswire
Oslo, 20 August 2018 - DNO ASA, the Norwegian oil and gas operator, today reported receipt of USD 69.03 million as payment for May 2018 crude oil deliveries to the export market from the Tawke license in the Kurdistan region of Iraq. The funds will be shared by DNO and partner Genel Energy plc pro-rata to the companies' interests in the license.
GEGYF GEGYY DTNOY GENL DTNOF

 
[Press] Genel Energy PLC: Update on Tawke PSC

2018-08-16 oilvoice
Genel Energy plc ('Genel') notes that DNO ASA, as operator of the Tawke PSC (Genel 25% working interest), has today issued an update on licence activity.
GEGYF GEGYY DTNOY GENL DTNOF

 
[Opinion] Oil Price, Savannah, Upland, RockRose, Bahamas Petroleum, and Finally…

2018-08-15 oilvoice
Oil Price After a quiet start to the week which I'm told livened up on Monday it has been another up and down week. Yesterday as I reported the market started by rising then with dollar strength and further aggro from Turkey it gave back all the gains. This was made worse after hours when the API stats came out, a build in crude stocks of 3.7m bbls was higher than the 2.5m forecast but then gasoline stocks unexpectedly drew by 1.
GEGYF BSHPF GENL SNEGF SVNNF CANIF UPL RBD SDRYF BPC GEGYY ZEE SOU PPCGF SAVP BSHPY PPC FPM

 
Genel Energy PLC (GEGYF) CEO Murat Özgül on Q2 2018 Results - Earnings Call Transcript

2018-08-14 seekingalpha
Okay. Good morning, ladies and gentlemen. I am Murat Özgül, CEO of Genel Energy and I would like to welcome you to our 2018 Half Year’s Results Presentation.
GEGYF GEGYY ARDN GENL

 
[Opinion] Oil Price, Savannah Petroleum, Faroe, Aminex, and Finally…

2018-08-08 oilvoice
Oil Price Oil has rallied modestly in the last couple of days as the market anticipated the Iranian sanctions starting up with phase 1 even though oil is not in the mix until November. Despite the protestations from other signatories from the nuclear agreement President Trump has made it perfectly clear that those who deal with Iran will not deal with the US.
SOLO HUR GEGYF GEGYY HRCXF GENL SAVP SVNNF WRL

 
Oil price recovery pours cash back into Genel Energy

2018-08-08 telegraph.co.uk
The revival of the global oil market has helped to triple the value of Genel Energy this year by pouring cash back into the beleaguered Kurdish oil group.
GEGYF GEGYY GENL

 
[Opinion] Genel Energy

2018-08-07 oilvoice
Interims to the end of June this morning from Genel who have put in what they call an ‘impressive performance' with which I concur. Key metric is cash generation with the company turning in over $10m per month and moving the company ‘rapidly' to a net cash position. This has been significantly helped by an impressive performance from Peshkabir where recent success with the drill bit has provided ‘the potential for both production to exceed guidance and for both proven and probable reserves to increase'.
GEGYF GEGYY GENL

 
[Press] Genel Energy PLC: Half-Year Results

2018-08-07 oilvoice
Genel Energy plc ('Genel' or 'the Company') announces its unaudited results for the six months ended 30 June 2018.
GEGYF GEGYY GENL

 
Norwegian Firm Exceeds Targeted Kurdistan Oil Production

2018-07-30 oilprice
Tsvetana is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing for news outlets such as iNVEZZ and…
GEGYF GEGYY DTNOY GENL DTNOF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 00B55Q3P3